Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth Stephen Thress, Cloud Peter Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015
Cited by 1,557 works. doi:10.1038/nm.3854
Authors
- Kenneth Stephen Thress
- Cloud Peter Paweletz
- Enriqueta Felip
- Byoung Chul Cho
- Daniel Stetson
- Brian Andrew Dougherty
- Zhongwu Lai
- Aleksandra A. Markovets
- Ana P. Vivancos
- Yanan Kuang
- Dalia Ercan
- Sarah E Matthews
- Mireille Cantarini
- J. Carl Barrett
- Pasi Antero Janne
- Geoffrey R. Oxnard
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib